# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-332750
Filing Date
2026-08-04
Accepted
2026-08-04 16:04:35
Documents
76
Period of Report
2026-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | sndx-20260630.htm iXBRL | 10-Q | 2373442
2 | EX-10.2 | sndx-ex10_2.htm | EX-10.2 | 93608
3 | EX-10.3 | sndx-ex10_3.htm | EX-10.3 | 52490
4 | EX-10.4 | sndx-ex10_4.htm | EX-10.4 | 58902
5 | EX-31.1 | sndx-ex31_1.htm | EX-31.1 | 15396
6 | EX-31.2 | sndx-ex31_2.htm | EX-31.2 | 15956
7 | EX-32.1 | sndx-ex32_1.htm | EX-32.1 | 16140
| Complete submission text file | 0001193125-26-332750.txt |  | 9127423

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | sndx-20260630.xsd | EX-101.SCH | 950023
80 | EXTRACTED XBRL INSTANCE DOCUMENT | sndx-20260630_htm.xml | XML | 1666356

Mailing Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017
Business Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37708 | Film No.: 261238463
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)